Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer

Trial Profile

Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Erlotinib (Primary) ; Capecitabine; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2016 Planned primary completion date changed from 1 Apr 2014 to 1 Apr 2018 as reported by ClinicalTrials.gov.
    • 04 Dec 2014 New trial record
    • 15 Nov 2012 Planned end date changed from Apr 2013 to Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top